Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen Inc (NASDAQ: BIIB) and Cooper Co (NYSE: COO)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen Inc (NASDAQ: BIIB) and Cooper Co (NYSE: COO).

Biogen Inc (NASDAQ: BIIB)

In a report released yesterday, Do Kim from BMO Capital reiterated a Hold rating on Biogen Inc (NASDAQ: BIIB), with a price target of $318. The company’s shares closed yesterday at $252.38.

According to TipRanks.com, Kim is a 4-star analyst with an average return of 13.3% and a 47.6% success rate. Kim covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Vertex Pharmaceuticals, and Cynapsus Therapeutics.

Currently, the analyst consensus on Biogen Inc is Moderate Buy and the average price target is $324.88, representing a 28.7% upside.

In a report issued on May 24, Cantor Fitzgerald also reiterated a Hold rating on the stock with a $277 price target.
Cooper Co (NYSE: COO)

BMO Capital analyst Joanne Wuensch reiterated a Buy rating on Cooper Co (NYSE: COO) yesterday and set a price target of $255. The company’s shares closed yesterday at $219.79, close to its 52-week high of $219.81.

According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 8.7% and a 70.4% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Cooper Co is Moderate Buy and the average price target is $226, representing a 2.8% upside.

In a report issued on May 30, Jefferies also reiterated a Buy rating on the stock with a $220 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.